Scale-up complete for Alzheimer's candidate

Manufacturing scale-up is complete for Avanex Life Sciences' alzheimer's treatment. A Phase I clinical trial of AVANEX 2-73 is set to begin in early 2010.

Some two kilograms of the drug candidate were manufactured by Sweden-based Syntagon, a provider of synthetic organic chemistry services. The contract manufacturer developed a five-step synthetic procedure for production of the compound. In addition, it developed and evaluated analytical methods for the production process.

The compound uses sigma receptors to correct dysfunction in the mitochondria and ultimately protect cells from oxidative stress, which is believed to be an underlying cause of the disease, according to a company announcement.

- here's the announcement

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.